Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
Treprostinil is a potent prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization Group I). Previously, treprostinil was available only in subcutaneous (SC) or intravenous (IV) formulations. Availability of an inhaled formulation of trep...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Medknow Publications
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641714/ |